Improvement in Cardiovascular Risk Prediction with Electronic Health Records. https://t.co/o4sEPk6sDN
RT @JuliaHCox: @eloder @sxbegle what's really interesting is #bmj QRISK2 performed better than new US calculator in a US population https:/…
RT @JuliaHCox: @eloder @sxbegle what's really interesting is #bmj QRISK2 performed better than new US calculator in a US population https:/…
RT @JuliaHCox: @eloder @sxbegle what's really interesting is #bmj QRISK2 performed better than new US calculator in a US population https:/…
RT @JuliaHCox: @eloder @sxbegle what's really interesting is #bmj QRISK2 performed better than new US calculator in a US population https:/…
@eloder @sxbegle what's really interesting is #bmj QRISK2 performed better than new US calculator in a US population https://t.co/SdHHW42V4f
RT @drshaun: Significant study- QRISK2 better discrimination v Framingham & ASCVD in CVD risk profiling #thankyouGPcontributors https://t.c…
RT @drshaun: Significant study- QRISK2 better discrimination v Framingham & ASCVD in CVD risk profiling #thankyouGPcontributors https://t.c…
Significant study- QRISK2 better discrimination v Framingham & ASCVD in CVD risk profiling #thankyouGPcontributors https://t.co/zQfhjtIdzZ
#QRISK2 outperformed ASCVD and Framingham in external validation of US patients from Mayo clinic https://t.co/SdHHW42V4f @GSCollins